2-(methylamino)ethanol, compound with sulphur dioxide

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Study period:

1978-04-20 to 1978-05-11 (first to last application)

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Acceptable non-GLP study, irrelevant route of exposure

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1979

Report date:

1979

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

BASF test: intraperitoneal application to mice.
The study was performed as described for the oral test (please refer to section 7.2.1), except that the test item preparations were injected into the peritoneal cavity.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2-(methylamino)ethanol, compound with sulphur dioxide

EC Number:

244-169-0

EC Name:

2-(methylamino)ethanol, compound with sulphur dioxide

Cas Number:

21049-70-7

Molecular formula:

C3H9NO.xO2S

IUPAC Name:

(oxo-λ⁴-sulfanylidene)oxidane; 2-(methylamino)ethan-1-ol

Details on test material:

Please refer to the section "Confidential details on test material" below.

Test animals

Species:

mouse

Strain:

NMRI

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: purchased from a breeder (Wiga)
- Age at study initiation: young adult
- Weight at study initiation (range of group mean values): 26-30 g (males), 24-26 g (females)
- Fasting period before study: 15-20 hours prior to the single administration
- Diet: Herilan MRH-Haltung (H. Eggersmann KG, Germany)

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

water

Details on exposure:

VEHICLE
- Concentration in vehicle: 70, 200 mg/mL
- Amount of vehicle: 10 mL/kg bw

MAXIMUM DOSE VOLUME APPLIED:
The concentrations of the dose formulations were adjusted to achieve the same dose volume, 10 mL/kg bw.

Doses:

700, 2000 mg/kg bw

No. of animals per sex per dose:

5 mice

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: the frequency of observations was not reported; body weight was determined once prior to treatment, on days 2-4, day 7 and 13 (only mean values reported)
- Necropsy of survivors performed: yes
- Other examinations performed: macroscopic examination of premature decedents

Statistics:

No statistical analysis was performed.

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 700 - < 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: significance level: 1 %

Mortality:

The mortality incidences after 14 days were:
0/10 at 700 mg/kg bw
10/10 at 2000 mg/kg bw
All deaths occurred within the first hour after the single i.p. treatment with the test item.

Clinical signs:

Dyspnoea, apathy and poor general condition were observed at both dose levels. Ruffled fur and spastic gait were seen at 700 mg/kg bw, and abnormal posture, spasms, clonic seizures and exsiccosis were noted at the high dose level of 2000 mg/kg bw only.

Body weight:

There was no test substance-related effect on mean body weights.

Gross pathology:

No macroscopic abnormalities were noted at necropsy of both survivors and premature decedents. No precipitates or residues of the dose formulation were present in the intraperitoneal cavity at gross pathological examination.